Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 108

Results For "human"

1142 News Found

TB Alliance partners with Lupin for non-exclusive anti-TB drug
Policy | September 06, 2021

TB Alliance partners with Lupin for non-exclusive anti-TB drug

According to WHO, over 1.5 million people died of TB in 2020


Novartis signs world’s first agreement with NHS, UK
News | September 03, 2021

Novartis signs world’s first agreement with NHS, UK

The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England


Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
Biotech | August 31, 2021

Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis

Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old


Acute therapies drive overall pharma growth in July: Ind-Ra
News | August 30, 2021

Acute therapies drive overall pharma growth in July: Ind-Ra

The segment delivered strong sales growth of 20% YoY


South Asia’s first advanced Genomics Research Centre open in Hyderabad
Biotech | August 28, 2021

South Asia’s first advanced Genomics Research Centre open in Hyderabad

The centre established by Nucleome Informatics will take up the sequencing of 5,000 Covid genomes and 500 human genomes in the coming months


Indian National Institute validates Livinguard’s face mask
Drug Approval | August 28, 2021

Indian National Institute validates Livinguard’s face mask

Textiles treated with the technology have also been proven to deactivate viruses, including SARS-CoV-2 (the virus that causes COVID-19).


Johnson & Johnson booster dose indicate impressive results
Drug Approval | August 26, 2021

Johnson & Johnson booster dose indicate impressive results

New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.


Sai Life Sciences is now a United Nations Global Compact (UNGC) signatory
News | August 26, 2021

Sai Life Sciences is now a United Nations Global Compact (UNGC) signatory

In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative


RedHill Biopharma's Opaganib demonstrates strong inhibition of COVID-19 Delta variant
Drug Approval | August 26, 2021

RedHill Biopharma's Opaganib demonstrates strong inhibition of COVID-19 Delta variant

Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease


Govt to offer incentives to support 75 start-ups in Tele-Medicine, AI and Digital Health
Startup | August 25, 2021

Govt to offer incentives to support 75 start-ups in Tele-Medicine, AI and Digital Health

The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge